Prometrium and Bupropion Interaction: What Patients and Prescribers Need to Know

How These Two Drugs Work

Prometrium is the brand name for oral micronized progesterone, approved by the FDA for endometrial protection in postmenopausal women receiving conjugated estrogens and for secondary amenorrhea. The FDA-approved prescribing information is available at accessdata.fda.gov. Bupropion is an atypical antidepressant and smoking-cessation aid classified as a norepinephrine-dopamine reuptake inhibitor (NDRI). The FDA label for bupropion hydrochloride extended-release tablets is publicly accessible.

Prometrium: Mechanism and Metabolism

Micronized progesterone is absorbed through the gastrointestinal tract and undergoes extensive first-pass hepatic metabolism. Progesterone pharmacokinetics after oral micronized administration are described in detail on PubMed. Key metabolites include 5-alpha-dihydroprogesterone and allopregnanolone. These neurosteroid metabolites are not inert bystanders; allopregnanolone is a positive allosteric modulator of GABA-A receptors, which is one reason oral progesterone tends to have sedative properties that vaginal or transdermal formulations lack. The neurosteroid activity of progesterone metabolites is reviewed in a 2019 Endocrine Reviews article indexed on PubMed.

Bupropion: Mechanism and Metabolism

Bupropion is primarily metabolized by CYP2B6 to its active metabolite hydroxybupropion, which contributes substantially to the drug's clinical effect. CYP2B6-mediated bupropion hydroxylation is established in the primary pharmacokinetic literature available through PubMed. A secondary pathway involves carbonyl reductases producing threohydrobupropion and erythrohydrobupropion. Bupropion itself is a potent CYP2D6 inhibitor, a property that matters when patients take additional medications cleared by that enzyme. The CYP2D6 inhibitory profile of bupropion is summarized in FDA drug interaction guidance documents.

The Core Pharmacokinetic Interaction: CYP2B6 Inhibition

Progesterone and several of its hepatic metabolites have been identified as inhibitors of CYP2B6 in in-vitro studies. A peer-reviewed in-vitro analysis of progestins as CYP2B6 inhibitors is indexed on PubMed. Because CYP2B6 is the dominant route of bupropion clearance, reduced enzyme activity raises hydroxybupropion formation and may allow parent bupropion to accumulate. Higher parent-drug concentrations are associated with a steeper seizure-risk curve.

What the In-Vitro Data Show

The inhibition constant (Ki) for progesterone at CYP2B6 falls in the low-micromolar range in human liver microsome assays. Published Ki values for endogenous steroids at CYP2B6 are available through the NCBI database. Clinical relevance depends on the free progesterone concentration at the hepatic enzyme site, which after a 200 mg oral dose of Prometrium at bedtime can transiently reach concentrations sufficient to produce partial inhibition. This is not a theoretical interaction that exists only in test tubes; the mechanistic basis is well-supported.

What Changes in Bupropion Exposure

When CYP2B6 activity is partially inhibited, the hydroxybupropion-to-bupropion ratio falls. The clinical significance of altered bupropion metabolite ratios is discussed in pharmacogenomic literature on PubMed. A lower ratio signals reduced clearance of the parent compound. For bupropion IR, SR, or XL, accumulation of parent drug over multiple doses could push trough plasma levels into ranges associated with dose-dependent adverse effects, including seizure. The magnitude of the effect is not yet quantified in a dedicated clinical pharmacokinetic trial, which is a gap in the published literature.

Seizure Risk: The Most Important Pharmacodynamic Concern

Seizure is the dose-limiting adverse effect of bupropion. The original immediate-release formulation was temporarily withdrawn from the US market in 1986 after seizures were reported at the 400 to 600 mg/day doses used in early anorexia trials. This regulatory history is documented in FDA archives. Current labeling sets a ceiling of 450 mg/day for any formulation and 150 mg per single dose for the IR product.

Incidence Data From the FDA Label

At doses up to 300 mg/day, the seizure incidence is approximately 0.1%. Titrating to the 300 to 450 mg/day range raises incidence to roughly 0.4%. These figures appear directly in the bupropion prescribing information indexed at FDA.gov. Any pharmacokinetic factor that raises effective drug exposure, including CYP2B6 inhibition from concurrent progesterone, shifts a patient toward the higher end of that risk curve without a corresponding dose increase on paper.

Risk Factors That Compound Seizure Susceptibility

The bupropion label explicitly identifies several conditions that lower the seizure threshold independently of dose. These include a prior seizure history, a diagnosis of bulimia or anorexia nervosa, abrupt benzodiazepine or alcohol discontinuation, and concomitant use of medications that themselves lower the seizure threshold. A comprehensive review of drug-induced seizure risk, including antidepressants, is available on PubMed. Patients starting Prometrium while already on bupropion may not recognize that their overall seizure risk has changed if no one has explained the interaction.

GABA-A Modulation by Allopregnanolone: A Double-Edged Effect

Allopregnanolone, the primary neurosteroid metabolite of oral progesterone, is actually a GABAergic agent and in isolation tends to be anticonvulsant. The anticonvulsant properties of allopregnanolone are reviewed in a dedicated PubMed-indexed article. This creates an apparent paradox: the pharmacodynamic effect of Prometrium's metabolites might partially counteract seizure risk, while the pharmacokinetic effect on CYP2B6 increases it. Clinically, the pharmacokinetic mechanism (elevated bupropion exposure) is considered the dominant concern because it is less predictable and varies with individual CYP2B6 genotype, dose timing, and metabolite production rates.

CYP2D6 Inhibition by Bupropion: A Separate Interaction Layer

Bupropion is classified as a strong CYP2D6 inhibitor by FDA criteria, with an in-vivo interaction ratio (AUC ratio) for CYP2D6 probe substrates exceeding 5-fold in some studies. The FDA's drug interaction table classifies bupropion as a strong CYP2D6 inhibitor. This matters for women on Prometrium plus bupropion who also take any of the following: tamoxifen (requires CYP2D6 activation to endoxifen), certain opioids such as codeine and tramadol, tricyclic antidepressants, or some antipsychotics. Tamoxifen-bupropion interactions via CYP2D6 inhibition are discussed in oncology pharmacology literature on PubMed.

Practical Polypharmacy Implications

A postmenopausal woman on HRT (estrogen plus Prometrium) who also takes bupropion for depression or smoking cessation may additionally be on a statin, a beta-blocker such as metoprolol (a CYP2D6 substrate), or a selective serotonin reuptake inhibitor. Metoprolol exposure increases significantly with bupropion co-administration, as shown in pharmacokinetic data indexed on PubMed. Each addition to the regimen requires a fresh look at the full interaction matrix, not just the Prometrium-bupropion pair in isolation.

Severity Classification and Interaction Databases

Major drug interaction databases (Lexicomp, Micromedex, and the FDA's own drug interaction table) classify the progesterone-bupropion interaction in the moderate category, primarily on the basis of the CYP2B6 inhibition mechanism rather than documented cases of clinical harm. The FDA table of clinically significant drug interactions supports this classification. "Moderate" does not mean ignorable; it means the combination can proceed with monitoring and appropriate precautions rather than requiring automatic substitution.

The 2022 Menopause Society guidelines note that the choice of progestogen formulation in HRT affects not just endometrial safety but also the metabolic and neurological profile of the regimen. The Menopause Society's 2022 hormone therapy position statement is available at menopause.org. Prescribers selecting a progestogen for a patient already on bupropion may find a non-oral route of progesterone, such as vaginal Prometrium or a levonorgestrel IUD, avoids the CYP2B6 interaction because first-pass hepatic metabolism is bypassed or reduced substantially.

Monitoring Protocol for Patients on Both Drugs

Before Starting the Combination

• Obtain a full seizure history, including febrile seizures in childhood.
• Screen for active or historical eating disorders (bulimia/anorexia).
• Document baseline alcohol intake; alcohol potentiates seizure risk with bupropion. The interaction between alcohol withdrawal and bupropion-associated seizures is discussed in the FDA label.
• Review the complete medication list for other CYP2B6 substrates and CYP2D6 substrates.
• Confirm the patient understands that dose changes in either drug should trigger a call to the prescriber.

During Concurrent Use

• Keep bupropion at the lowest dose that achieves the therapeutic goal. For depression, the minimum effective dose is 150 mg/day of the XL formulation; for smoking cessation, the standard is 150 mg twice daily of SR (300 mg/day total), well below the 450 mg ceiling. Bupropion dosing for smoking cessation is detailed in the FDA-approved label.
• Avoid dose escalation of bupropion while Prometrium dose is being titrated upward.
• Reassess at every HRT cycle change. Prometrium is often cycled (e.g., 200 mg for 12 days per month), meaning CYP2B6 inhibition may wax and wane. The cyclic dosing schedule for Prometrium is described in the FDA prescribing information.
• Ask about new neurological symptoms at each visit: unusual dizziness, myoclonic jerks, or brief lapses of awareness.

When to Consider an Alternative Progestogen

If seizure risk factors are present, switching from oral Prometrium to a low-dose levonorgestrel IUD (52 mg, releasing 20 mcg/day) for endometrial protection removes the hepatic CYP2B6 inhibition concern entirely. The endometrial protective effect of the levonorgestrel IUD in HRT is supported by evidence reviewed on PubMed. Vaginal micronized progesterone (Endometrin, Crinone) also avoids significant first-pass metabolism, though its use specifically for endometrial protection in HRT is off-label in the US. Vaginal progesterone pharmacokinetics differ substantially from oral, as reviewed in PubMed-indexed literature.

Patient Counseling Points

Patients need plain-language explanations, not pharmacokinetic jargon. The core message is that taking Prometrium and bupropion together may cause bupropion to build up slightly in the body, which raises the chance of side effects including, in rare cases, a seizure.

Key counseling statements for clinical practice:

1. "Do not increase your bupropion dose without telling your prescriber you are also taking Prometrium."
2. "If you start feeling unusually dizzy, shaky, or have any episode of blacking out, seek emergency care and call our office the same day."
3. "Alcohol and bupropion are a bad combination even without Prometrium in the picture. Adding Prometrium makes that warning more important." This aligns with bupropion label language on alcohol use.
4. "Do not stop either medication suddenly without guidance. Abrupt discontinuation of bupropion can itself cause rebound effects."

The North American Menopause Society states: "Progestogens differ in their pharmacological properties, and these differences may influence tolerability and safety in individual patients." NAMS 2022 position statement, available at menopause.org. That statement directly supports choosing a non-oral progestogen route when a bupropion-CYP2B6 interaction is a concern.

Special Populations

CYP2B6 Poor Metabolizers

Approximately 3 to 5% of patients of European ancestry carry two loss-of-function CYP2B6 alleles and are classified as poor metabolizers. CYP2B6 genetic polymorphism prevalence data are available through the PharmGKB database, with linked PubMed literature. These individuals already have reduced bupropion clearance at baseline. Adding a CYP2B6 inhibitor such as oral progesterone in a poor metabolizer creates a compounded exposure increase. Pharmacogenomic testing is not yet standard of care before starting bupropion, but it is available and may be useful when a patient has unexpected sensitivity to the drug. The role of CYP2B6 pharmacogenomics in bupropion dosing is discussed in CPIC guideline literature indexed on PubMed.

Patients Using Bupropion for Smoking Cessation During HRT Initiation

A common clinical scenario: a perimenopausal woman is prescribed Wellbutrin SR 150 mg twice daily for smoking cessation and, simultaneously, her gynecologist starts her on a standard continuous-combined HRT regimen including Prometrium 100 mg nightly. Neither prescriber may be aware of the other's prescription. Polypharmacy and the need for medication reconciliation in perimenopausal women is addressed in women's health literature on PubMed. The 12-week standard smoking-cessation course means the overlap is time-limited, which reduces but does not eliminate risk. In this window, the 300 mg/day bupropion dose is already at the lower end of the therapeutic range, so the CYP2B6 inhibition effect adds a manageable but real margin of exposure increase.

Postmenopausal Women With Mood Disorders

Women on long-term bupropion for major depressive disorder who require continuous Prometrium as part of their HRT regimen face ongoing, not transient, CYP2B6 inhibition. Bupropion for major depressive disorder in women is reviewed in evidence-based psychiatry literature on PubMed. For this group, the lowest effective bupropion dose and periodic reassessment of whether a non-oral progestogen could replace Prometrium are the two most actionable risk-reduction steps.

What the Evidence Gap Means for Clinical Decision-Making

No dedicated randomized pharmacokinetic trial has measured bupropion AUC changes during co-administration of oral micronized progesterone 100 mg or 200 mg in human subjects. The interaction is inferred from in-vitro enzyme kinetics, population pharmacokinetic modeling, and extrapolation from stronger CYP2B6 inhibitors such as ticlopidine. The ticlopidine-bupropion interaction trial, which quantifies the maximal CYP2B6 inhibition effect on bupropion exposure, is indexed on PubMed. That study found a 4.5-fold increase in bupropion AUC with strong CYP2B6 inhibition. Progesterone's inhibitory potency at CYP2B6 is lower than ticlopidine's, so the clinical effect is almost certainly smaller, but "smaller" is not the same as "absent."

The FDA Drug Interaction guidance document recommends that sponsors and clinicians apply a mechanistic static model to predict DDI magnitude before concluding no clinical study is needed. FDA drug interaction guidance for industry is available at fda.gov. Applying that framework to progesterone at peak hepatic concentrations after a 200 mg oral dose suggests a weak-to-moderate inhibitor classification, predicting AUC increases in the 20 to 50% range for bupropion. A 25% increase in a patient already at 300 mg/day effective bupropion exposure is clinically non-trivial.

Summary Table: Interaction Profile at a Glance

| Feature | Detail | |---|---| | Interaction mechanism | CYP2B6 inhibition by progesterone metabolites | | Severity classification | Moderate (interaction database consensus) | | Clinical consequence | Potential bupropion AUC increase (estimated 20 to 50%) | | Most serious risk | Dose-dependent seizure from elevated bupropion exposure | | Offsetting factor | Allopregnanolone GABAergic (anticonvulsant) effect | | Bupropion dose ceiling | 450 mg/day per FDA label regardless of co-medications | | Preferred mitigation | Use lowest bupropion dose; consider non-oral progestogen route | | Monitoring | Seizure history, alcohol use, full medication reconciliation |